Skip to main content

Ciphergen Opens New East Coast Proteomics Center

NEW YORK, March 14 - Ciphergen Biosystems of Fremont, Calif., said Wednesday it opened a new center in Malvern, Pa., to conduct proteomic research for the company’s customers.

The Biomarker Discovery Center’s first project will entail a clinical stratification pilot study for an unnamed pharmaceutical company. The center will also support the company’s cancer biomarker project with Johns Hopkins School of Medicine. 

"The opening of this center is the next step in our providing advanced proteomics services to our pharmaceutical and biotechnology clients," William Rich, CEO of Ciphergen, said in a statement.

"In particular, we see a major opportunity in using our ProteinChip System to perform differential protein expression analysis to discover biomarkers that may have major applications in pre-clinical and clinical drug development," Rich said.

The ProteinChip System is designed to be used for protein discovery, characterization, and assay development. 

Larry McClain, previously vice president of R&D at Centocor Diagnostics, will manage the new facility, which will also employ two research scientists. 

Separately on Wednesday, Ciphergen’s CEO was named a member of Genomica’s board of directors.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.